Predicting lung disease outcomes in people with myositis
Myositis-ILD Risk Prediction Models and Endotypes
This project combines medical information and genetic markers to predict which people with myositis will have worsening interstitial lung disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-11193816 on NIH RePORTER |
What this research studies
If you have myositis and lung involvement, researchers will use medical records, blood tests for HLA genetics, and other biomarkers from a large group of patients across North America to build a tool that forecasts disease course. They will refine a preliminary model that suggested certain HLA types help predict progression and will follow patients over time to see how well the new model works in diverse groups. The team will compare the new tool to existing scores like GAP-ILD and add novel clinical and lab markers to improve accuracy. The goal is to identify biological subgroups (endotypes) that could guide more personalized treatment choices.
Who could benefit from this research
Good fit: Adults with myositis who have or are suspected to have interstitial lung disease, particularly those receiving care at participating North American centers, are the ideal candidates.
Not a fit: People without myositis, those whose lung disease has a different cause, or patients not represented in the study populations are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, this could help doctors identify who needs stronger therapy and who may avoid unnecessary aggressive treatment.
How similar studies have performed: Standard tools like GAP-ILD have performed poorly in myositis-ILD, but preliminary models combining clinical data and HLA genotypes showed promise and now need larger, diverse validation.
Where this research is happening
Philadelphia, United States
- University of Pennsylvania — Philadelphia, United States (Active)
Researchers
- Principal investigator: Johnson, Cheilonda — University of Pennsylvania
- Study coordinator: Johnson, Cheilonda
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.